The U.S. Food and Drug Administration (FDA) granted approval on August 5, 2026, for a seasonal influenza vaccine utilizing mRNA technology, specifically designed for adults aged 50 and older. This development signals a shift in pharmaceutical manufacturing, moving away from the traditional, labor-intensive methods that previously required unique processes for every individual vaccine candidate.
Messenger RNA (mRNA) technology functions by delivering genetic instructions to cells, encapsulated within lipid nanoparticles, to produce specific proteins. Because these drugs are programmable via DNA templates, they offer a level of consistency and predictability that can reduce financial risks and development timelines. Unlike conventional pharmaceuticals, mRNA-based treatments are currently characterized by a short half-life, making them particularly well-suited for vaccines that require only a brief exposure to trigger a lasting immune response.
However, the technology faces challenges regarding how the immune system distinguishes between therapeutic mRNA and viral threats. The body often identifies mRNA entering through endosomes as a sign of infection, triggering inflammatory responses. Scientists have mitigated this by modifying mRNA building blocks—a discovery recognized with the 2023 Nobel Prize—and by working to remove double-stranded RNA impurities that can occur during production.
Looking ahead, researchers are exploring applications beyond immunization, such as using mRNA to deliver CRISPR-Cas9 for gene editing. While these therapies show promise for treating conditions like hereditary transthyretin amyloidosis, experts emphasize that further innovation is needed. Future advancements, including the use of computational algorithms to improve mRNA stability and the engineering of more precise production enzymes, will be essential to expand the technology's use for treatments requiring longer-term protein expression.
Source: The Conversation
No comments yet. Be the first to share your thoughts.